Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in …

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to three years and delayed tumor recurrence in patients with resected pancreatic ductal…#phase1 #bnt122 #pdac #phase2 #autogene #genentechinc #genentech #rochegroup #inest #bntx
Source: Reuters: Health - Category: Consumer Health News Source Type: news